NASDAQ: TSBXTurnstone Biologics Corp Stock
$2.76-0.14 (-4.83%)
Updated Apr 26, 2024
TSBX Price
$2.76
Fair Value Price
-$0.90
Market Cap
$63.75M
52 Week Low
$1.63
52 Week High
$13.20
P/E
-0.58x
P/B
0.65x
P/S
1.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.31M
Earnings
-$55.20M
Gross Margin
100%
Operating Margin
-287.4%
Profit Margin
-286.1%
Debt to Equity
0.14
Operating Cash Flow
-$66M
Beta
3.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TSBX Overview
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TSBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TSBX ($2.76) is overvalued by 407.28% relative to our estimate of its Fair Value price of -$0.90 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TSBX ($2.76) is not significantly undervalued (407.28%) relative to our estimate of its Fair Value price of -$0.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TSBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TSBX due diligence checks available for Premium users.
Be the first to know about important TSBX news, forecast changes, insider trades & much more!
TSBX News
Valuation
TSBX fair value
Fair Value of TSBX stock based on Discounted Cash Flow (DCF)
Price
$2.76
Fair Value
-$0.90
Undervalued by
407.28%
TSBX ($2.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TSBX ($2.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TSBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TSBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.58x
Industry
14.88x
Market
41.14x
TSBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
5.85x
TSBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TSBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.5M
Profit Margin
0%
TSBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TSBX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$112.8M
Liabilities
$14.1M
Debt to equity
0.14
TSBX's short-term assets ($102.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TSBX's short-term assets ($102.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TSBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.5M
Investing
-$5.3M
Financing
-$169.0k
TSBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TSBX vs Biotech Stocks
Turnstone Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.